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CD81 T Cell–Mediated Skin Disease in Mice Lacking
IRF-2, the Transcriptional Attenuator of
Interferon-a/b Signaling
protein tyrosine phosphatase SHP-1 is induced and in-
hibits EPO response (Klingmuller et al., 1995). Recently,
a family of feedback inhibitors consisting of cytokine-
inducible SH2-containing protein (CIS) and its related
members has been identified (Kharitonenkov et al.,
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It is well known that type I IFNs (IFN-a/b) are essentialHongo 2-2-1, Bunkyo-ku
for host defense against viral and bacterial infec-Tokyo 113-0033
tions (DeMaeyer and DeMaeyer-Guignard, 1988; Vilcek,Japan
1990). In addition, IFN-a/b is also known to be involved
in many immunoregulatory processes, such as natural
killer cell activation (Biron et al., 1999) and proliferation/Summary
survival of CD81 T cells (Tough et al., 1996; Marrack et
al., 1999). Notably, treatment of chronic myeloid leuke-The balanced action of cytokines is known to be criti-
mia and multiple sclerosis patients with high doses ofcal for the maintenance of homeostatic immune re-
IFN-a or IFN-b is sometimes associated with autoim-sponses. Here, we report the development of an in-
mune-like symptoms resembling those of systemic lu-flammatory skin disease involving CD81 T cells, in mice
pus erythematosus, thyroiditis, rheumatoid arthritis, orlacking the transcription factor, interferon regulatory
psoriasis (Quesada and Gutterman, 1986; Funk et al.,factor-2 (IRF-2). CD81 T cells exhibit in vitro hyper-
1991; Belardelli and Gresser, 1996; Dusheiko, 1997). Fur-responsiveness to antigen stimulation, accompanied
thermore, experimental manipulations of the IFN-a/bwith a notable upregulation of the expression of genes
system in the mouse have been shown to cause autoim-induced by interferon-a/b (IFN-a/b). Furthermore,
mune diseases and lymphopenia (Stewart et al., 1993;both disease development and CD81 T cell abnormality
Binder et al., 1997; Lin et al., 1998). These observationsare suppressed by the introduction of nullizygosity to
suggest that, like those of other cytokines, the actionsthe genes that positively regulate the IFN-a/b signaling
of IFN-a/b must also be controlled to prevent them frompathway. IRF-2 may represent a unique negative regu-
exerting potentially harmful effects on the host.
lator, attenuating IFN-a/b-induced gene transcription,
IFN-a/b stimulation results in the activation/induction
which is necessary for balancing the beneficial and
of several transcriptional activators, including the het-
harmful effects of IFN-a/b signaling in the immune erotrimeric transcription factor, IFN-stimulated gene
system. factor 3 (ISGF3), consisting of Stat1, Stat2, and inter-
feron regulatory factor-9 (IRF-9) (Darnell et al., 1994;
Introduction Bluyssen et al., 1996; Taniguchi et al., 2000). On the
other hand, little is known about the negative regulatory
Cytokines are critical mediators of immune responses. mechanism of the IFN-a/b signaling pathway. IRF-2, one
However, they are not always beneficial to the host, of the members of the IRF family of transcription factors,
because many cytokines are multifunctional and often is ubiquitously and constitutively expressed (Nguyen et
invoke antigen-nonspecific response (Leonard, 1999). al., 1997; Mamane et al., 1999; Taniguchi et al., 2000).
In this context, regulatory mechanisms suppressing the Although previous in vitro studies suggested that IRF-2
harmful effects of cytokines have been described. For acts as a repressor of IRF-1 (Harada et al., 1989; Nguyen
example, immunosuppressive cytokines, such as in- et al., 1997; Mamane et al., 1999; Taniguchi et al., 2000),
terleukin (IL)-10 and transforming growth factor-b, coun- it is still unknown how IRF-2 functions in vivo.
terbalance the detrimental effects of other cytokines, Here we provide evidence that unlike previous in vitro
which would otherwise lead to T cell-mediated tissue studies, IRF-2 functions as a negative regulator of gene
destruction (Shull et al., 1992; Kuhn et al., 1993; Kulkarni expression by antagonizing IFN-a/b-activated ISGF3.
et al., 1993). In addition, negative feedback mechanisms, We first show the spontaneous development of an in-
flammatory skin disease involving CD81 T cells in micewhich suppress prolonged cytokine responses that may
lacking IRF-2 (IRF-22/2 mice). We then demonstrate thathave potentially harmful effects, are operational in cyto-
the absence of IRF-2 indeed causes uncontrolledkine signaling. During erythropoietin (EPO) signaling, the
IFN-a/b responses, which result in aberrant CD81 T cell
activation. Our current study suggests a novel mecha-
nism underlying the negative regulation of IFN-a/b sig-‡ To whom correspondence should be addressed (e-mail: tada@
naling by IRF-2, namely, transcriptional attenuation, thatm.u-tokyo.ac.jp).
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Figure 1. Development of Skin Disease in IRF-22/2 Mice
(A) Macroscopic appearance of skin inflammation, for 2-, 3-, and 5-month-old animals.
(B) Course of the skin disease. Disease scoring was carried out as follows: 0, no symptoms; 1, hair loss in an area ,1 cm2; 2, hair loss in an
area $1 cm2 without excoriation; 3, excoriation but no ulceration; and 4, lesions with ulceration. Cumulative data (n 5 8 for each genotype)
obtained from two litters derived from crosses between IRF-21/2 and IRF-22/2 mice. Open circles and closed circles represent IRF-21/2 and
IRF-22/2 mice, respectively.
(C) Histopathology of skin disease. Skin sections from 5-month-old IRF-22/2 mice (2/2) and control littermates (1/2) were stained with
hematoxylin and eosin. Note thickening of the epidermis in IRF-22/2 mice skin.
(D) Enzyme immunohistochemical analysis of the skin. Keratinocytes in the basal and suprabasal layers were positively stained in IRF-22/2
mice for BrdU, Ki67, and ICAM-1/CD54. Cellular nuclei were counterstained with methyl green. 1/2, control littermates; 2/2, IRF-22/2 mice.
Original magnification 3100.
(E) Immunofluorescence staining of the skin. CD41 and CD81 T cells exhibit yellow fluorescence. Cellular nuclei were counterstained with
propidium iodide. 1/2, control littermates; 2/2, IRF-22/2 mice. Original magnification 3100.
Results observed that all homozygous mutant animals started to
exhibit signs of progressive cutaneous inflammation,
including erythema accompanied by hair loss that finallyDevelopment of an Inflammatory Skin Disease
in IRF-22/2 Mice extended over the whole trunk (Figures 1A and 1B), as
early as 8 weeks after birth. Excoriation of these skinWe first backcrossed IRF-22/2 mice generated pre-
viously (Matsuyama et al., 1993) with C57BL/6 mice, in lesions occurred, eventually resulting in ulcer formation.
Histopathological analysis showed thickening of theorder to investigate the potential role of IRF-2 in vivo. We
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epidermis (Figure 1C), apparently due to the proliferation ease was also observed in B cell-deficient IRF-22/2
(IRF-22/2mMT/mMT) mice, making it highly unlikely thatof keratinocytes in the basal epidermis as revealed by
bromodeoxyuridine (BrdU) incorporation in vivo and antibodies play any role in the pathogenesis of the skin
disease (Table 1, Experiment 1). Collectively, these re-staining with anti-Ki67 antibodies, which stained the
nuclei of proliferating cells (Figure 1D). In addition, kera- sults further indicate the selective requirement of CD81
T cells for the development of the skin disease.tinocytes in the basal and suprabasal layers appeared
to be activated, because they expressed intercellular
adhesion molecule-1 (ICAM-1/CD54; Figure 1D). These Hyperresponsiveness of CD81 T Cells
features are similar to those found in psoriasis (Carroll et to Antigen Stimulation
al., 1995; Paukkonen et al., 1995; Stern, 1997). However, In order to examine how IRF-2 deficiency affects CD81
abnormalities not found in psoriasis were also observed T cells, we stimulated spleen cells isolated from young,
below the epidermis, including a disorganized muscle disease-free IRF-22/2 mice (H-2b) in vitro with irradiated
layer and associated prominent fibrosis (Figure 1C). We spleen cells obtained from allogenic BALB/c mice (H-2d).
also noticed that both CD41 and CD81 T cells infiltrated As shown in Figure 2C, IRF-22/2 CD81 T cells exhibited
into the basal dermis of the affected skin in IRF-22/2 continual activation in response to allogenic stimulation,
mice (Figure 1E), suggesting an underlying immunopa- while a majority of similarly stimulated IRF-21/2 CD81
thogenetic mechanism for this skin disease. T cells entered the resting phase on day 4 of culture,
as judged by the forward scatter (FCS) profile and the
expression of activation markers CD25 and CD69. SuchSelective Involvement of CD81 T Cells
prolonged activation resulted in the marked proliferationin the Inflammatory Skin Disease
of CD81 T cells in these cultures, and CD81 T cellsCD41 and CD81 T cell infiltration into the skin lesion
constituted about 60% of the surviving IRF-22/2 spleenprompted us to examine if these cells contribute to the
cells on day 5 as compared with 25% in IRF-21/2 andpathogenesis of the skin disease. For this purpose, be-
wild-type spleen cells (Figure 2D; data not shown). Thefore the onset of the skin disease, we induced the deple-
fraction of CD41 T cells was found to be reduced intion of CD41 or CD81 T cells selectively, by injecting
proportion to the increased number of CD81 T cells. Aanti-CD4 or CD8 antibodies, respectively. As shown in
similar observation was also made with T cells fromFigure 2A, the depletion of CD81 T cells due to the
draining lymph nodes (data not shown). In addition, theinjection of anti-CD8 antibodies clearly delayed the on-
abnormal response of IRF-22/2 CD81 T cells was alsoset of the skin disease in comparison with control mice
observed when they were stimulated with irradiatedtreated with phosphate-buffered saline (PBS) alone. Ap-
spleen cells from bm1 mice carrying mutations in theproximately 4 weeks after the commencement of anti-
MHC class I gene, but not with those from MHC classCD8 antibody injection, however, the skin disease be-
II mutant bm12 mice (McKenzie et al., 1979; Reimanncame detectable, albeit in a milder form than that seen
et al., 1985; Asano et al., 1990; data not shown). Thesein control animals. We observed that although no CD81
results indicate that CD81, but not CD41, T cells derivedT cells were found early after the commencement of
from IRF-22/2 mice are hyper-responsive to antigeninjection, a substantial number of CD81 T cells were
stimulation in vitro.regenerated (depicted as CD42B2202CD31 cells) in pe-
ripheral blood samples from mice with a mild form of
the skin disease (Figure 2A). We infer that neutralizing Accumulation of Polyclonal, Memory-Phenotype
CD81 T Cells in IRF-22/2 Miceantibodies against rat anti-mouse CD8 antibodies were
produced by the repeated injection of the latter, thereby The prolonged activation of CD81 T cells would affect
the cellular composition of the immune system inallowing the regeneration of CD81 T cells and the devel-
opment of a mild form of skin disease. On the other hand, IRF-22/2 mice. As described previously, the numbers of
T (CD41 and CD81) and B cells in the spleen were notCD41 T cells (CD82 CD31 cells) remained completely
depleted even at 6 weeks after the commencement of significantly altered in young, disease-free IRF-22/2
mice (Matsuyama et al., 1993; data not shown). How-antibody injection (Figure 2B), presumably due to the
suppression of the production of neutralizing antibodies ever, at the age of approximately 3 months, when the
skin disease started to develop, the population ofby the initial depletion of CD41 helper T cells. However,
even in the complete absence of CD41 T cells, the skin CD44high Ly-6C1 cells (i.e., activated/memory-phenotype
CD81 T cells) became prominent, and after 5 months,disease developed with the same kinetics as that in
PBS-treated control IRF-22/2 mice (Figure 2B). These the percentage of these cells exceeded 80% (Figure
3A). We often observed that as the disease advanced,results indicate the involvement of CD81, but not CD41
T cells, in the development of the skin disease. draining lymph nodes (inguinal) in IRF-22/2 mice became
enlarged and contained at least three times as manyIn order to clarify further the involvement of CD81 T
cells in the pathogenesis of the skin disease, we gener- cells as those in their heterozygous littermates, probably
reflecting the inflammatory reactions in the skin (Figureated IRF-22/2 mice congenitally lacking CD81 T cells, by
crossing IRF-22/2 mice with b2-microglobulin-deficient 3B). Notably, CD44high Ly-6C1 cells were predominant in
the CD81 T cell population in the lymph nodes (Figure(b2m2/2) mice or CD8-deficient (CD82/2) mice. Up to 4
months after birth, no skin symptoms were observed in 3C). In contrast, this CD44high Ly-6C1 subset of T cells
represents a rather minor fraction of CD41 T cells inIRF-22/2b2m2/2 mice and IRF-22/2 CD82/2 mice (Table
1, Experiment 1), based on macroscopic and histological the spleen and the enlarged lymph nodes even in 3-
to 5-month-old IRF-22/2 mice with severe skin diseaseexamination. In contrast, IRF-22/2 mice lacking CD41 T
cells (IRF-22/2CD42/2 mice) developed the skin disease (data not shown). Because the expression of neither
CD25 nor CD69 was enhanced on CD44high Ly-6C1 CD81(Table 1, Experiment 1). Development of the skin dis-
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Figure 2. Essential Involvement of Activated CD81, but not CD41, T Cells in the Skin Disease of IRF-22/2 Mice
IRF-22/2 mice were treated with anti-CD8a (A) or anti-CD4 (B) monoclonal antibodies (closed circles) or PBS alone (open circles). Arrows
indicate an injection. Disease scores are as defined in Figure 1B. Each circle corresponds to an individual IRF-22/2 mouse. Peripheral blood
samples were obtained by partial bleeding immediately before antibody injection at times marked with large circles and analyzed for the
presence of CD81 [CD31CD4-B2202; (A)] or CD41 [CD31CD82; (B)] T cells.
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Table 1. Skin Inflammation in IRF-22/2 Mice Additionally Lacking Selective Overexpression of IFN-Inducible
b2m, CD8, CD4, the m Membrane Exon, IFNAR1, and IRF-9 Genes in IRF-22/2 Cells
In contrast to IFN-a/b gene expression, a notable differ-Genotype Incidence
ence was found in the expression of some IFN-inducibleExperiment 1 IRF-22/2 20/20
genes (Figure 4), such as the 29, 59-oligoadenylate syn-IRF-22/2b2m1/2 9/9
thetase (OAS) and the IRF-7 genes, which are known toIRF-22/2b2m2/2 0/3
IRF-22/2CD81/2 6/6 be dependent on ISGF3 (Guille et al., 1994; Nonkwelo
IRF-22/2CD82/2 0/3 et al., 1997; Au et al., 1998; Sato et al., 1998). The expres-
IRF-22/2CD41/2 6/6 sion levels of mRNAs for these genes were found to be
IRF-22/2CD42/2 4/4
elevated several fold in the skin, and to a lesser extentIRF-22/2mMT/1 10/10
in the spleen obtained from IRF-22/2 mice that had notIRF-22/2mMT/mMT 4/4
yet developed the disease (2-month-old animals; FigureExperiment 2 IRF-22/2IFNAR11/2 11/11
IRF-22/2IFNAR12/2 0/7 4B) as well as from those with the skin disease (5-month-
IRF-22/2IRF-9 (ISGF3g)1/2 15/15 old animals; data not shown). Notably, the abnormally
IRF-22/2IRF-9 (ISGF3g)2/2 0/9 elevated expression of mRNAs for these IFN-inducible
Skin disease was examined at 4 months of age. Cumulative data genes in IRF-22/2 mice was no longer observed when
obtained from three litters for b2m2/2 and mMT mutants, two litters a null mutation for IRF-9 (ISGF3g) was introduced, which
for CD8 and CD4 mutants, four litters for IFNAR1 mutant, and five abolished the IFN-induced formation of ISGF3 (Kimura
litters for IRF-9 (ISGF3g) mutant mice are shown. et al., 1996) (IRF-22/2IRF-92/2 mice; Figure 4C). These
observations indicate that IRF-2 antagonizes the func-
tions of ISGF3. Interestingly, the basal expression levels
T cells (Figure 3D), and their FSC profile (data not shown) of these mRNAs in the spleen and skin of IRF-92/2 mice
indicated that these cells were in the resting phase, the were even less than those in control mice (Figure 4C),
accumulated cells may represent resting memory cells. indicating the low-level activation of ISGF3 by the spon-
Analysis of the TCR Vb usage in the CD81 T cell popula- taneously produced IFN-a/b in unmanipulated animals.
tion in the spleen and lymph nodes in IRF-22/2 mice, in Because IFN-a/b can induce the expression of these
which more than 80% is comprised of CD44high Ly-6C1 genes even in wild-type cells that normally express
cells, did not reveal any significant skewing of Vb usage IRF-2, IRF-2 does not repress gene induction completely
(Figure 3E), indicating that these CD81 T cells in IRF-22/2 (see Discussion). It is unlikely that the enhancement of
mice are polyclonal. OAS and IRF-7 gene expressions contributes to the T
cell-mediated skin disease. In this regard, it is notewor-
Normal Spontaneous Expression of IFN-a/b Genes thy that the mRNA expressions for two IFN-inducible
in IRF-22/2 Mice chemokine genes, IP-10 (Vanguri and Farber, 1990) and
How does the absence of IRF-2 result in the CD81 T murine monokine induced by g interferon (MIG), were
cell-mediated skin disease? Because it is known that also found to be abnormally enhanced in the skin of
IRF-2 binds to interferon-stimulated response elements IRF-22/2 mice (Figures 4B and 4C). In fact, it is known
(ISREs) in the promoters of many IFN-inducible genes, that these chemokines affect T cell migration, attracting
it is conceivable that the IFN-a/b system is dysregulated activated T cells expressing their common receptor,
in the absence of IRF-2, and that such dysregulation is CXCR3 (Miller and Krangel, 1992; Farber, 1997). More-
responsible for the disease development. In this context, over, much like those of the aforementioned IFN-induc-
we first examined the expression of IFN-a/b mRNAs and ible genes, these mRNA expressions were also abol-
that of IFN-inducible genes in several tissues including ished in IRF-92/2 or IRF-22/2IRF-92/2 mice, indicating
the affected and unaffected skin of IRF-22/2 mice. It was that the expression of these genes is also dependent
found that the expression of IFN-a/b mRNAs was not on ISGF3 (Figure 4C). The restricted overexpression of
detectable by conventional RNA blotting analysis of total IP-10 and MIG genes in the skin is interesting, because
RNA isolated from the skin of either IRF-22/2 mice or this is the site showing infiltration of CD81 T cells re-
their heterozygous littermates (data not shown). How- sponsible for the inflammatory skin disease. In fact, by
ever, by using a sensitive reverse transcriptase-poly- semiquantitative RT-PCR analysis, CXCR3 mRNA ex-
merase chain reaction (RT-PCR) technique, both IFN-a pression was selectively detected in the skin lesion of
and IFN-b mRNAs were detected at equivalent levels in IRF-22/2 mice (Figure 4D). In addition, the population of
the skin as well as in other tissues (Figure 4A). This the CXCR31 CD81 T cells is dramatically increased in
observation is consistent with previous reports showing the spleen of IRF-22/2 mice (K. O., unpublished observa-
that low-level IFN-a/b production is often detected in tion). These observations support the notion that it is
cells, even in the absence of viral infection (Bocci, 1985; the CXCR31 CD81 T cells that are infiltrating into the
skin lesion. To test directly IFN-stimulated induction ofGresser, 1990; Takaoka et al., 2000).
(C) Spleen cells isolated from 3-month-old IRF-22/2 mice (2/2) or their control littermates (1/2) were stimulated with irradiated allogenic
BALB/c spleen cells. FSC profile and expression of activation markers, CD25 and CD69, on day 4 of the culture. Histograms for CD81 T cells
are shown.
(D) CD41 and CD81 T cell ratios of spleen cells on day 0 and day 4 of the culture. Numbers indicate percentages of cells within the corresponding
quadrants. Fractions of CD81 (closed circles) and CD41 (open circles) T cells in the surviving control (upper panel) and IRF-22/2 (lower panel)
cells on the days indicated. Each symbol represents the mean 6 SD for three independent cultures. Data shown in (D) are representative of
three individual experiments.
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the expression of these genes in the skin we intrader- essential role in the pathogenesis of the skin disease.
In this regard, we provide evidence of uncontrolled, con-mally injected mouse recombinant IFN-b into wild-type
and IRF-22/2 mice, and mRNAs from the skin were ana- tinual IFN-a/b signaling in the skin of IRF-22/2 mice, as
revealed by the hyper-responsiveness to, but not thelyzed. As shown in Figure 4E, induction of mRNA expres-
sion for both IRF-7 and IP-10 genes was observed in overproduction of, IFN-a/b. Such an observation was
made in young IRF-22/2 mice that had not yet developedwild-type mice; however, this induction was much higher
in IRF-22/2 mice. These results further indicate that in the skin disease, as well as in adult IRF-22/2 mice with
the skin disease, indicating that the continual, excessivethe absence of IRF-2, cells become hyper-responsive
to IFN-a/b stimulation. IFN-a/b signaling is not a secondary, but a primary,
cause for the inflammatory skin disease. Our results
suggest that such a continual, weak ISGF3 activationImportance of IFN-a/b Signaling in the
Pathogenesis of Skin Lesions and CD81 by IFN-a/b signaling is harmful unless properly attenu-
ated by IRF-2. Thus, our current study reveals a unique,T Cell Hyper-Responsiveness
In order to examine whether aberrant IFN-a/b responses physiologically important function of IRF-2 as a mediator
balancing the beneficial and harmful effects of IFN-a/bin the absence of IRF-2 indeed contribute to the patho-
genesis of the skin disease, we inactivated the IFN-a/b signaling. This negative regulatory mechanism mediated
by IRF-2 is distinct from that of other cytokine systems,signaling pathway in IRF-22/2 mice by introducing muta-
tions in either the IFNAR1 or the IRF-9 (ISGF3g) gene such as protein tyrosine phosphatases and CIS and its
family members, which are also known as important(IRF-22/2IFNAR12/2 and IRF-22/2IRF-92/2 mice, respec-
tively). Interestingly, these double-mutant mice did not negative feedback regulators of cytokine responses
(Endo et al., 1997; Kharitonenkov et al., 1997; Starr etshow any signs of the skin disease (Figure 5A; Table 1,
Experiment 2). These results demonstrate that IFN-a/b al., 1997; Yoshimura, 1998; Losman et al., 1999).
Our current study indicates for the first time a definitesignaling leading to ISGF3 activation is indeed responsi-
ble for the development of the skin disease in IRF-22/2 link between IRF-2 and the IFN-a/b signaling pathway.
IFN-a/b seems to be produced spontaneously in themice.
In view of the fact that CD81 T cells are involved in skin as well as in other tissues at various levels in both
IRF-22/2 mice and control littermates, as judged by thethe skin disease, we also examined whether or not the
abnormalities seen in IRF-22/2 CD81 T cells are also presence of IFN-a and -b mRNAs. Because the mice
were kept under specific pathogen-free conditions, it isrelated to this excessive IFN-a/b signaling. As shown in
Figure 5B, the selective outgrowth of IRF-22/2CD81 T unlikely that this expression is induced by viral or bacte-
rial infection. We infer that the major function of IRF-2cells in response to allogenic stimulation was not ob-
served in IRF-22/2IFNAR12/2 spleen cells. As expected, is not to suppress IFN-a/b responses completely but to
control the chronic, weak IFN-a/b signaling by attenuat-the level of activation of CD81 T cells on day 4 of culture,
as judged from the FSC profile and activation marker ing ISGF3-mediated induction of gene expression. Nota-
bly, the expression of IP-10 and MIG mRNAs is mostexpressions, was also reduced in IRF-22/2IFNAR12/2
spleen cells (Figure 5B). Furthermore, similar restora- prominent in the skin, while IFN-a/b gene expression is
found in many tissues (Figure 4). These tissue-specifiction of CD81 T cell response was also observed in
IRF-22/2IRF-92/2 spleen cells (data not shown). These elevations of mRNA expression may explain why macro-
scopic inflammation is found predominantly in the skinobservations collectively indicate that the abnormal re-
sponse of CD81 T cells derived from IRF-22/2 mice is of IRF-22/2 mice. The mechanism(s) by which the ex-
pression of these genes is selectively elevated in thealso due to excessive IFN-a/b signaling involving ISGF3.
skin remains unknown at present. It is possible that the
promoters of these genes are additionally controlledDiscussion
by a tissue-specific factor (or factors) that may act in
cooperation with ISGF3.We have reported here the development of an inflamma-
tory skin disease in mice lacking the transcription factor The exact mechanism by which IRF-2 negatively regu-
lates the function of ISGF3 is unknown. It is known thatIRF-2. In view of our current results that IRF-22/2 mice
carrying null mutations in one of the molecules involved both IRF-2 and ISGF3 bind to the common target se-
quence, ISRE (Yamagata et al., 1996). Unlike ISGF3,in the IFN-a/b signaling pathway (IRF-22/2IFNAR12/2
and IRF-22/2IRF-92/2 mice) do not develop the skin dis- IRF-2 is a stable nuclear protein, and it is constitutively
expressed in many cell types (Harada et al., 1989). Inease, we conclude that the IFN-a/b system plays an
Figure 3. Accumulation of Memory-Phenotype CD81 T Cells in Aged IRF-22/2 Mice
(A) Flow cytometric analysis of spleen cells obtained from 2-, 3-, and 5-month-old IRF-22/2 (2/2) and their control littermates (1/2). Profiles
show the expression of CD44 and Ly-6C on CD81 T cells.
(B) The number of cells in the spleen and the inguinal lymph nodes is shown for 5-month-old mice.
(C) Profiles for lymph node CD81 T cells are also shown for 5-month-old mice. CD81 T cells of the memory-phenotype (CD44high Ly-6C1) are
boxed, and the percentages of these cells are shown.
(D) The expression of activation markers CD25 and CD69 on CD81 T cells in the spleen obtained from 5-month-old IRF-22/2 mice and their
control littermates.
(E) TCR Vb usage in spleen and lymph node CD81 T cells in 5-month-old IRF-22/2 (solid bars) and wild-type control (open bars) mice. Results
are indicated as the percentages of cells positive for each TCR Vb within CD81 T cells. These data are representative of two independent
analyses (A, C, D).
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Figure 4. mRNA Expression of IFN-a, IFN-b, and IFN-Inducible Genes in IRF-22/2 Mice
(A) RT-PCR analysis of mRNAs for IFN-a, IFN-b, and b-actin in tissues isolated from 2-month-old IRF-22/2 (2/2) and control (1/2) mice.
cDNAs were synthesized from total RNA (1 mg), diluted as indicated, and amplified by PCR. The result obtained with 5-fold diluted cDNA is
shown.
(B) Northern blot analysis showing mRNAs hybridized with probes for OAS, MIG, IP-10, and b-actin in various tissues obtained from 2-month-
old control (1/2) and IRF-22/2 (2/2) mice.
(C) Expression of OAS, IRF-7, IP-10, MIG, and b-actin mRNA in the skin and spleen obtained from 2-month-old IRF-21/2 IRF-91/2 (control),
IRF-21/2 IRF-92/2 (IRF-92/2), IRF-22/2 IRF-91/2 (IRF-22/2), and IRF-22/2 IRF-92/2 (dKO) mice.
(D) RT-PCR analysis of mRNAs for CXCR3 in the skin isolated from 2-month-old IRF-22/2 (2/2) and control (1/2) mice. cDNA synthesis and
PCR were performed as shown in (A).
(E) IFN-b (1 3 104 U) was injected intradermally into IRF-21/2 or IRF-22/2 mice. Six hours after administration, mRNAs were prepared from
the skin injected with IFN-b or PBS. Northern blot analysis was performed as shown in (C).
addition, it has a rapid on-off rate for ISRE binding (D. scriptional attenuation,” may be operational in cytokine
systems other than the IFN-a/b system.Thanos, personal communication), suggesting that this
factor continuously interacts with ISRE elements of IFN- Recent studies have shown that IFN-a/b signaling can
induce bystander, nonantigen specific proliferation/sur-inducible genes, in order to maintain ISGF3 actions in
equilibrium (Figure 6). Although less likely, the possibility vival of memory CD81 T cells (Tough et al., 1996; Marrack
et al., 1999). In addition, it has been reported that thethat IRF-2 affects IFN-a/b-induced gene expression by
ISGF3 via an indirect mechanism (e.g., through the in- proliferation of IFN-a/b-induced, memory-phenotype
CD81 T cells is, at least in part, mediated by IFN-inducedduction of another suppressive factor) cannot be strictly
ruled out. Whatever the precise mechanism, this type IL-15 (Zhang et al., 1998). Our preliminary results indi-
cate that the expression of IL-15 mRNA is also enhancedof negative regulation, which may also be termed “tran-
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Figure 5. Both Development of the Skin Disease and the CD81 T Cell Abnormalities in IRF-22/2 Mice Are Dependent on IFN-a/b Signaling
(A) Appearance of the skin in 2- to 3-month-old IRF-21/2IRF-91/2 (control), IRF-21/2IRF-92/2 (IRF-92/2), IRF-22/2IRF-91/2 (IRF-22/2), and
IRF-22/2IRF-92/2 mice. Photographs of two animals for each genotype are shown.
(B) Spleen cells obtained from 3-month-old IRF-21/2IFNAR11/2 (control), IFNAR12/2IRF-21/2 (IFNAR12/2), IFNAR11/2IRF-22/2 (IRF-22/2), and
IFNAR12/2IRF-22/2 mice were stimulated with irradiated BALB/c spleen cells. Cells were harvested after 4 days of culture and stained for
CD4 and CD8. Numbers represent the percentages of cells within the boxes. Histograms for FSC profile and the expression of CD25 and
CD69 on the CD81 T cells are shown.
in the skin, but not in the spleen, of IRF-22/2 mice (S. H., in response to alloantigens in vitro. A critical question
remains as to which IFN-induced gene product (or prod-unpublished observation). Therefore, it is possible that
the local proliferation of CD81 T cells is mediated by IL- ucts) is responsible for the hyper-responsiveness of
CD81 T cells. In view of our results that the depletion15. However, an abnormality in CD81 T cells themselves
can also be instrumental in the accumulation of memory- of CD81 T cells prevented the disease development in
IRF-22/2 mice, it is likely that accumulated memory-phenotype CD81 T cells, as suggested by the IFN-a/b
signal-dependent outgrowth of IRF-22/2 CD81 T cells phenotype CD81 T cells are directly involved in the
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may envisage the involvement of multiple events: (1)
recruitment of CD81 T cells to the skin; (2) hyper-respon-
siveness of these T cells, associated with their produc-
tion of proinflammatory cytokines; and (3) activation/
proliferation of other cell type (or types), such as kera-
tinocytes in the skin, which would further stimulate these
T cells. Once initiated, these events would induce a
“vicious cycle” of inflammation. In this regard, it is note-
worthy that the expression of mRNAs for chemokines,
IP-10, and MIG, is selectively enhanced in the skin but
not in the spleen (Figure 4), implicating that they may
be expressed by a cell (or cells) of nonhematopoietic
origin. In fact, keratinocytes are among the best produc-
ers of IP-10 and MIG chemokines (Luster and Ravetch,
1987). Moreover, it is well known that IP-10 production is
induced locally in regions of skin inflammation (Gottlieb,
1990; Smoller et al., 1990). It is noteworthy that the
expression of mRNA for CXCR3, an IP-10/MIG receptor
that is expressed in activated T cells (Miller and Krangel,
1992; Farber, 1997), is selectively upregulated in the
affected skin lesion (Figure 4D), suggesting the involve-
ment of this chemokine system. Our preliminary data
suggest that this chemokine system is involved in IFN-
mediated, CD81 T cell activation (K. O., unpublished
observation). However, further work will be required to
determine to what extent the abnormal upregulation of
IP-10/MIG expression contributes to the disease.
The skin disease in IRF-22/2 mice represents a unique
example of CD81 T cell-mediated pathology, caused by
the absence of transcriptional attenuation of spontane-
ous IFN-a/b signaling. In this regard, it is worth notingFigure 6. IRF-2, the Attenuator of IFN-a/b Signaling
that treatment of some patients with a high dose of(A) Small amounts of IFN-a/b, which are produced spontaneously,
IFN-a/b is associated with the development of autoim-induce ISGF3 formation continuously. However, IRF-2, a stable nu-
clear protein expressed in many cells, tickles the ISRE sites on IFN- mune-like syndromes, including psoriasis, an inflamma-
inducible genes and competes with ISGF3 for these sites, thereby tory skin disease in which CD81 T cells have been impli-
attenuating IFN-a/b signals. cated in playing a pathogenic role (Baker et al., 1987;
(B) In contrast, in the absence of IRF-2, the action of ISGF3 is
Schlaak et al., 1994; Gottlieb et al., 1995). Given theunregulated, leading to the continual, elevated expression of IFN-
considerable differences in the histopathological char-inducible genes.
acteristics between the skin disease in IRF-22/2 mice
and psoriasis, caution must be exercised in relating
the pathogenic mechanism in IRF-22/2 mice to that ofpathogenetic process. In a similar context, it has been
human psoriasis. Nevertheless, our present study sug-shown that the activation of CD81 T cells upon viral
gests the possibility that IRF-2 or other molecules in-infection or injection of poly-(I):(C) results in various im-
volved in IFN-a/b signaling, are involved in the develop-munopathologies manifested as tissue injury (Cannon
ment of psoriasis in some cases.et al., 1988; Graham et al., 1991; Ehl et al., 1998; Selin
et al., 1998). Because both viral infection and poly-(I):(C)
Experimental Procedurestreatment induce the production of IFN-a/b, the mecha-
nism underlying these immunopathologies may be simi- Mice
lar to that of the pathogenesis of the lesions in IRF-22/2 Mice lacking IRF-2 (Matsuyama et al., 1993) or IRF-9/ISGF3g (Kimura
mice, which are induced by excessive IFN-a/b signaling. et al., 1996) were generated as previously described, and were back-
crossed four to six times with C57BL/6. Mice lacking the m mem-Another intriguing issue is whether IRF-22/2 CD81 T
brane exon (mMT/mMT) (Kitamura et al., 1991), a kind gift from Prof.cells or bone marrow-derived cells are sufficient to in-
D. Kitamura (Tokyo Science University), and those lacking IFNAR1duce skin inflammation. In this regard, we transferred
(B&K Universal Group Ltd.) were backcrossed more than ten and
IRF-22/2 CD81 T cells or bone marrow cells into irradi- more than five times with C57BL/6, respectively. b2m2/2 (Koller et
ated wild-type mice, but neither skin disease nor accu- al., 1990), CD82/2(Fung-Leung et al., 1991), and CD42/2 (Rahemtulla
mulation of memory-phenotype CD81 T cells was ob- et al., 1991) mice with a C57BL/6 background were obtained from
the Jackson Laboratory. MHC mutants, bm1 and bm12, were kindlyserved in the recipient animals (S. H., unpublished
provided by Dr. H. Watanabe (Niigata University). All mice wereobservation). Therefore, it is likely that the disease devel-
maintained under specific pathogen-free conditions in the animalops as a result of the interaction of CD81 T cells with
facility of the University of Tokyo.
another type (or types) of cells, such as activated kera-
tinocytes in IRF-22/2 mice. Histopathologic Analysis and In Vivo BrdU Labeling
It is likely that multiple genes, upregulated by the lack Formalin-fixed skin sections (3 mm) prepared from dorsal skin speci-
mens of the mice were stained with hematoxylin and eosin. Immuno-of IRF-2, are involved in the disease development. One
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histochemistry was carried out on 3-mm cryostat sections using an A. Takaoka, K. Ishiodori, M. Isobe, S. Kano, T. Irie, T. Tachikawa,
T. Kuroki, M. Kashiwagi, A. Kosugi, K. Tamaki, H. Ihn, and M. Komineimmunoperoxidase method. After fixation in acetone or paraformal-
dehyde, sections were incubated with primary antibodies, followed for helpful suggestions; M. Nakajima and J. Nemoto for help in
photographical works; and D. Kitamura and H. Watanabe for mMTby incubation with appropriate biotin-labeled secondary antibodies,
and developed with streptavidin conjugated with horseradish perox- mice and bm mutant mice, respectively. This work was supported
in part by the Japan Society for the Promotion of Science, Researchidase or fluorescein isothiocyanate (FITC). The chromogens used
were 3-amino-9-ethylcarbazole for anti-ICAM-1 (clone 3E2) antibody for the Future Program; by a special grant for Advanced Research
on Cancer from the Ministry of Education, Science, and Culture ofstaining, and 3,3-diaminobenzidine tetrachloride for anti-BrdU
(clone BU1/75) and anti-Ki-67 (rabbit polyclonal, Novocastra) anti- Japan; by the Kao Foundation for Arts and Sciences; and by the
Human Frontier Science Program. S. Hida is on leave of absencebody staining. Anti-CD4 (clone GK1.5) and anti-CD8a (clone 53–6.72)
antibodies were used for immunofluorescence analysis of cryostat from Nippon Schering K.K.
sections. To detect BrdU incorporation, cryostat sections were pre-
pared from mice that had received BrdU (0.5 mg per mouse) intraper- Received April 5, 2000; revised September 28, 2000.
itoneally 6 hr before sacrifice.
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